Long-term effects of a sustained-release preparation of acipimox on dyslipidemia and glucose metabolism in non-insulin-dependent diabetes mellitus

Metabolism: Clinical and Experimental

Volumn 47, Issue 3, 1998, Pages 250-256

  Davoren, P M ^a   Kelly, W ^b   Gries, F A ^b   Hubinger, A ^b   Whately Smith, C ^b   Alberti, K G M M ^b  

^a GOLD COAST UNIVERSITY HOSPITAL   (Australia)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACIPIMOX; GLUCOSE; NEUTRAL INSULIN; PLACEBO;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DYSLIPIDEMIA; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; HYPERGLYCEMIA; INSULIN RESISTANCE; INTRAVENOUS DRUG ADMINISTRATION; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUSTAINED RELEASE PREPARATION; TREATMENT OUTCOME;

EID: 0031886869     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0026-0495(98)90252-9     Document Type: Article

References (47)

1. Golay A, Chen YDI, Reaven GM: Effect of differences in glucose tolerance on insulin's ability to regulate carbohydrate and free fatty acid metabolism in obese individuals. J Clin Endocrinol Metab 62:1081-1088, 1986
2. Garland PB, Newsholme EA, Randle PJ: Regulation of glucose uptake by muscle. IX. Effects of fatty acids and ketone bodies, and of alloxan diabetes and starvation, on pyruvate metabolism and on lactate/pyruvate and 1-glycerol 3-phosphate/dihydroxyacetone phosphate concentration ratios in rat heart and rat diaphragm muscles. Biochem J 93:665-678, 1964
3. Nuutila P, Koivisto VA, Knuuti J, et al: Glucose-free fatty acid cycle operates in human heart and skeletal muscle in vivo. J Clin Invest 89:1767-1774, 1992
4. Bevilacqua S, Buzzigoli G, Bonadonna R, et al: Operation of Randle's cycle in patients with NIDDM. Diabetes 39:383-389, 1990
5. Ferrannini E, Barrett EJ, Bevilacqua S, et al: Effect of fatty acids on glucose production and utilization in man. J Clin Invest 72:1737-1747, 1983
6. Boden G, Jadali F: Effects of lipid on basal carbohydrate metabolism in normal men. Diabetes 40:686-692, 1991
7. Saloranta C, Koivisto V, Widen E, et al: Contribution of muscle and liver to glucose-fatty acid cycle in humans. Am J Physiol 264:E599-E605, 1993
8. Bevilacqua S, Bonadonna R, Buzzigoli G, et al: Acute elevation of free fatty acid levels leads to hepatic insulin resistance in obese subjects. Metabolism 36:502-506, 1987
9. Vaag A, Skott P, Damsbo P, et al: Effect of the antilipolytic nicotinic acid analogue acipimox on whole-body and skeletal muscle glucose metabolism in patients with non-insulin dependent diabetes mellitus. J Clin Invest 88:1282-1290, 1991
10. Fulcher GR, Walker M, Catalano C, et al: Metabolic effects of suppression of nonesterified fatty acid levels with acipimox in obese NIDDM subjects. Diabetes 41:1400-1408, 1992
11. Puhakainen I, Yki-Jarvinen H: Inhibition of lipolysis decreases lipid oxidation and gluconeogenesis from lactate but not fasting hyperglycaemia or total hepatic glucose production in NIDDM. Diabetes 42:1694-1699, 1993
12. Fulcher GR, Walker M, Catalano C, et al: Acute metabolic and hormonal responses to the inhibition of lipolysis in non-obese patients with non-insulin-dependent (type 2) diabetes mellitus: Effects of acipimox. Clin Sci 82:565-571, 1992
13. Davoren PM, Alberti KGMM: The effect of 24-hour suppression of plasma nonesterified fatty acid levels on glucose and lipid metabolism in NIDDM. Diabet Nutr Metab 8:17-23, 1995
14. Worm D, Henriksen JE, Vaag A, et al: Pronounced blood glucose-lowering effect of the antilipolytic drug acipimox in non-insulin dependent diabetes mellitus patients during a 3-day intensified treatment period. J Clin Endocrinol Metab 78:717-721, 1994
15. Saloranta C, Taskinen M, Widen E, et al: Metabolic consequences of sustained suppression of free fatty acids by acipimox in patients with NIDDM. Diabetes 42:1559-1566, 1993
16. Molnar GD, Berge KG, Rosevear JW, et al: The effect of nicotinic acid in diabetes mellitus. Metabolism 13:181-189, 1964
17. Garg A, Grundy SM: Nicotinic acid therapy for treatment of dyslipidaemia in non-insulin dependent diabetes mellitus. JAMA 264:723-726, 1990
18. Fucella L, Goldaniga G, Lovisolo P, et al: Inhibition of lipolysis by nicotinic acid and acipimox. Clin Pharmacol Ther 28:790-795, 1980
19. Fulcher GR, Catalano C, Walker M, et al: A double blind study of the effect of acipimox on serum lipids, blood glucose control and insulin action in non-obese patients with type 2 diabetes mellitus. Diabet Med 9:908-914, 1992
20. Vaag AA, Beck-Nielsen H: Effects of prolonged acipimox treatment on glucose and lipid metabolism and on in vivo insulin sensitivity in patients with non-insulin dependent diabetes mellitus. Acta Endocrinol (Copenh) 127:344-350, 1992
21. Dean JD, McCarthy S, Betteridge DJ, et al: The effect of acipimox in patients with type 2 diabetes and persistent hyperlipidaemia. Diabet Med 9:611-615, 1992
22. Koev D, Cvrkalova A, Rybka J, et al: Improvement of lipoprotein lipid composition in type II diabetic patients with concomitant hyperlipoproteinaemia by acipimox treatment. Diabetes Care 16:1285-1290, 1993
23. Seed M, O'Connor B, Perombelon N, et al: The effect of nicotinic acid and acipimox on lipoprotein(a) concentration and turnover. Atherosclerosis 101:61-68, 1993
24. Carlson LA, Hamsten A, Asplund A: Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid. J Int Med Res 226:271-276, 1989
25. Harano Y, Ohgaku S, Hidaka H, et al: Glucose, insulin and somatostatin infusion for the determination of insulin sensitivity. J Clin Endocrinol Metab 45:1124-1127, 1977
26. Heine RJ, Home PD, Poncher M, et al: A comparison of 3 methods for assessing insulin sensitivity in subjects with normal and abnormal glucose tolerance. Diabetes Res 2:113-120, 1985
27. Knox DP, Jones DG: Automated enzymatic determination of plasma free fatty acids by centrifugal analysis. J Automated Chem 6:152-154, 1984
28. Stappenbeck R, Hodson AW, Skillen AW, et al: Optimized methods to measure acetoacetate, 3-hydroxybutyrate, glycerol, alanine, pyruvate, lactate and glucose in human blood using a centrifugal analyser with a fluorimetric attachment. J Automatic Chem 12:213-220, 1990
29. Chuang-Stein C: Summarising laboratory data with difference ranges in multicenter clinical trials. Drug Inform J 26:77-84, 1992
30. Taskinen M, Nikkila EA: Effects of acipimox on serum lipids, lipoproteins and lipolytic enzymes in hypertriglyceridaemia. Atherosclerosis 69:249-255, 1988
31. Ball MJ, Vella M, Reckless JPD, et al: Acipimox in the treatment of patients with hyperlipidaemia: A double blind trial. Eur J Clin Pharmacol 31:201-204, 1986
32. Stirling C, McAleer M, Reckless JPD, et al: Effects of acipimox, a nicotinic acid derivative, on lipolysis in human adipose tissue and on cholesterol synthesis in human jejunal mucosa. Clin Sci 68:83-88, 1985
33. Yang CY, Gu ZW, Xie YH, et al: Effects of gemfibrozil on very-low-density lipoprotein composition and low-density lipoprotein size in patients with hypertriglyceridemia or combined hyperlipidemia. Atherosclerosis 126:105-116, 1996
34. Haffner S, Orchard T, Stein E, et al: Effect of simvastatin on Lp(a) concentrations. Clin Cardiol 18:261-267, 1995
35. Slunga L, Johnson O, Dahlen GH: Changes in Lp(a) lipoprotein levels during the treatment of hypercholesterolaemia with simvastatin. Eur J Clin Pharmacol 43:369-373, 1992
36. Groop LC, Bonadonna RC, Delprato S, et al: Glucose and free fatty acid metabolism in non-insulin dependent diabetes mellitus. J Clin Invest 84:205-213, 1989
37. Hoffman J, Spengler M: Efficacy of 24-week monotherapy with acarbose, glibenclamide, or placebo in NIDDM patients. Diabetes Care 17:561-566, 1994
38. Coniff RF, Shapiro JA, Seaton TB, et al: Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus. Am J Med 98:443-451, 1995
39. DeFronzo RA, Goodman AM, and the Multicenter Metformin Study Group: Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 333:541-549, 1995
40. Wolffenbuttel BH, Nijst L, Sels JP, et al: Effects of a new oral hypoglycaemic agent, repaglinide, on metabolic control in sulphonylurea treated patients with NIDDM. Eur J Clin Pharmacol 45:113-116, 1993
41. Draeger E: Clinical profile of glimeperide. Diabetes Res Clin Pract 28:8139-8146, 1995 (suppl)
42. Bogardus C, Lillioja S, Howard BV, et al: Relationships between insulin secretion, insulin action and fasting plasma glucose concentration in non-diabetic and non-insulin dependent diabetic subjects. J Clin Invest 74:1238-1246, 1984
43. Golay A, Swislocki ALM, Chen YI, et al: Relationships between plasma free fatty acid concentration, endogenous glucose production, and fasting hyperglycaemia in normal and non-insulin-dependent diabetic individuals. Metabolism 36:692-696, 1987
44. Fulcher GR, Walker M, Farrer M, et al: Acipimox increases glucose disposal in normal man independent of changes in plasma nonesterified fatty acid concentration and whole-body lipid oxidation rate. Metabolism 42:308-314, 1993
45. Davoren PM, Motala A, Alberti KGMM: The effect of acipimox on glucose disposal in non-insulin dependent diabetes is dependent on the lowering of nonesterified fatty acid levels. Diabet Nutr Metab 8:99-104, 1995
46. Lovisolo PP, Briatico-Vangosa G, Orsini G, et al: Pharmacological profile of a new anti-lipolytic agent: 5-Methyl-pyrazine-2-carboxylic acid 4-oxide (acipimox). I. Mechanism of action. Pharmacol Res Commun 13:151-161, 1981
47. Christie AW, McCormick DKT, Emmison N, et al: Mechanism of anti-lipolytic action of acipimox in isolated rat adipocytes. Diabetologia 39:45-53, 1996